Evidence map›Paper›PMID 35145059›Full record

ArticleBlood cancer journal2022

Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma.

Fushen Sha, Michelle Okwali, Anna Alperovich, Philip C Caron, Lorenzo Falchi, Audrey Hamilton, Paul A Hamlin, Steven M Horwitz, Erel Joffe, Niloufer Khan and 17 more

Abstract read
In one paragraph

Article in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Fushen ShaDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-3262-323X
Michelle OkwaliDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Anna AlperovichDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Philip C CaronDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lorenzo FalchiDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1531-3838
Audrey HamiltonDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Paul A HamlinDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Steven M HorwitzDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Erel JoffeDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-7883-289X
Niloufer KhanDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Anita KumarDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Matthew J MatasarDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alison J MoskowitzDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ariela NoyDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-3001-4898
Colette OwensDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lia M PalombaDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-5099-9156
Ildefonso Rodriguez-RiveraDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
David StrausDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Gottfried von KeudellDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Andrew D ZelenetzDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Joachim YahalomDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ahmet DoganDepartment of Pathology, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-6576-5256
Heiko SchöderDepartment of Radiology, Nuclear Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Venkatraman E SeshanDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-9258-2698
Gilles SallesDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-9541-8666
Anas YounesDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-0001-4133
Connie L BatleviDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. leec@mskcc.org.ORCID 0000-0002-9036-9463

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Between 1998 and 2009, a total of 295 patients (median age 58, 53% females) with newly diagnosed early-stage follicular lymphoma (FL) were managed at Memorial Sloan Kettering Cancer Center. Approximately half of patients (137, 46%) underwent initial observation and half (158, 54%) immediate treatment: radiation alone (n = 108), systemic treatment alone (n = 29), or combined modality treatment (n = 21). Median follow-up was 8.4 years (range 0.3-17.2), and 10-year overall survival (OS) was 87.2%. OS was similar between initially-observed and immediately-treated patients (hazard ratio [HR]: 1.25, 95% CI: 0.67-2.36, p = 0.49). For patients receiving radiation alone, 5-year OS was 98.0%. Patients selected for systemic therapy alone had high-risk baseline features and had shorter OS than patients treated with radiation alone (HR 3.38, 95% CI 1.29-8.86, p = 0.01). Combined modality treatment did not yield superior survival compared with radiation alone (P > 0.05) but was associated with better progression-free survival (HR 0.36, 95% CI 0.14-0.90, p = 0.03). The rate of transformation increased steadily over time and was 4.2% at 5 years and 10.8% at 10 years. This modern-era analysis rationalized the role of initial observation in patients with early-stage FL although patients receiving radiation therapy also demonstrate excellent outcome.

Indexed as

Lymphoma, FollicularAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyFemaleHumansMaleMiddle AgedNeoplasm StagingProgression-Free SurvivalTreatment Outcome

Identifiers

PMID35145059
PMCPMC8831497

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.